Simeprevir Heads to Gate with Upbeat Phase III Data
By Marie Powers
Friday, October 18, 2013
Medivir AB reported preliminary data from two Phase III studies of simeprevir conducted by partner Janssen R&D Ireland, suggesting the once-daily NS3/4A protease inhibitor could additionally benefit individuals with genotype 1 hepatitis C virus (HCV) co-infected with HIV-1 and patients with genotype 4 chronic HCV who have compensated liver disease.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.